Heart Failure February 22, 2024
Reprieve Cardiovascular Looks to Transform ADHF Decongestion Management February 22, 2024
Reprieve Cardiovascular emerged this week, announcing a hefty $42M Series A round and an even bigger mission to “transform the standard of care” for patients with acute decompensated heart failure.
Surgeries & Interventions February 15, 2024
FDA Panel Strongly Supports Abbott TriClip TEER February 15, 2024
The FDA expert advisory panel votes are in, and they’re pointing in an overwhelmingly positive direction for Abbott's TriClip tricuspid edge-to-edge repair treatment.
Obesity Care February 12, 2024
Gastric Bypass Surgery’s Durable Hypertension Impact February 12, 2024
The associations between obesity and hypertension are widely known, but a new JACC study reveals that weight-reducing gastric bypass surgery has a significant and lasting impact on patients’ need for antihypertensives.
Surgeries & Interventions February 8, 2024
Biosense Webster’s Varipulse PFA Data Impresses at AF Symposium February 8, 2024
Biosense Webster might be a later entry into the AFib pulsed field ablation segment, but new trial data presented at the AF Symposium suggests that the J&J subsidiary’s Varipulse PFA system could make a big impact when it does hit the market.
Surgeries & Interventions February 5, 2024
Edwards EVOQUE First FDA-Approved Transcatheter Tricuspid Regurgitation Treatment February 5, 2024
Edwards Lifesciences ended last week with the biggest structural interventions launch that we’ve seen in some time, announcing the FDA approval of its EVOQUE transcatheter tricuspid valve replacement system.
Surgeries & Interventions February 1, 2024
SAVR’s Value in the TAVR Era February 1, 2024
Procedure trends certainly suggest that we’ve entered the TAVR era, but a pair of new studies show that surgical aortic valve replacement (SAVR) is a far better option for many younger and healthier patients who are increasingly seen as TAVR candidates.
Pharmaceuticals January 29, 2024
Vascepa’s ACS Advantage January 29, 2024
Amarin’s fish oil-based Vascepa (icosapent ethyl, aka IPE) made its mark in 2018’s REDUCE-IT trial after achieving a 25% MACE reduction among high-risk statin users, and new post hoc analysis of the same data suggests that IPE might have an even greater benefit among patients who recently had acute coronary syndrome.
Remote Care January 25, 2024
CardioSignal Looks to Expand CVD Detection through Patients Phones January 25, 2024
Expanding access to heart disease detection is one of cardiology’s biggest challenges, and Finnish startup CardioSignal just raised $10M to address that challenge using one of the most accessible devices in the world - the smartphone.
Cardiovascular Disease January 22, 2024
Lipoprotein(a)’s Outsized Per-Particle Risks January 22, 2024
A pair of JACC studies layed what might be a new scientific foundation for all that research showing that people with high lipoprotein(a) have elevated cardiovascular risks.
Cardiology Practices January 18, 2024
Private Equity’s Cardiovascular Expansion January 18, 2024
Private equity’s massive expansion across US healthcare has largely skipped cardiology, but a new JAMA paper suggests that cardiovascular clinicians should expect PE to have a much greater influence within their specialty going forward.
Cardiology Pharmaceuticals January 11, 2024
Strong-HF Analysis Supports Quick HF Medication Optimization January 11, 2024
Secondary analysis of Strong-HF trial data highlighted the benefits of quickly bringing heart failure patients up to full guideline-directed medical therapy (GDMT), showing that rapid uptitration to optimal doses reduces readmissions and mortality, while improving quality of life.
Cardiology Pharmaceuticals January 8, 2024
Applied Therapeutics’ AT-001 Trial Misses Mark January 8, 2024
Applied Therapeutics saw its shares fall 40% late last week after revealing that its diabetic cardiomyopathy drug candidate AT-001 didn’t meet its phase 3 trial’s primary endpoint. However, the trial did show enough “encouraging results” for Applied to assert that AT-001 could still become the first diabetic cardiomyopathy treatment.
Cardiology Pharmaceuticals January 4, 2024
Cytokinetics’s Aficamten Delivers in SEQUOIA-HCM Trial January 4, 2024
Topline results from Cytokinetics’ SEQUOIA-HCM phase 3 trial suggests that 2024 could be the company’s best year ever, showing that its investigative obstructive hypertrophic cardiomyopathy drug aficamten significantly improved all primary and secondary endpoints.
Electrophysiology December 18, 2023
Medtronic’s PulseSelect Becomes First FDA-Approved PFA System December 18, 2023
The AFib pulsed field ablation treatment era officially began in the US last week, following the FDA approval of Medtronic’s PulseSelect Pulsed Field Ablation System for the treatment of both paroxysmal and persistent atrial fibrillation.
Cardiology December 14, 2023
Laza Medical Emerges with Vision for Ultrasound-Guided Cath Lab Procedures December 14, 2023
Cath lab procedures have always been synonymous with X-ray fluoroscopy guidance, but this week’s emergence of interventional imaging startup Laza Medical highlights a growing focus on ultrasound guidance.
Artificial Intelligence December 11, 2023
Us2.ai’s Echo Strain Validation December 11, 2023
A new study showed that Us2.ai’s AI echo algorithm can interpret echocardiographic strain images with similar accuracy as conventional measurements, highlighting how AI can democratize cardiac strain exams and improve heart failure assessments.
Pharmaceuticals December 7, 2023
Roche Enters Obesity Arena with Carmot Acquisition December 7, 2023
The already massive GLP-1 obesity drug segment might have gained a major future competitor last week, following Roche’s acquisition of weight loss biotech Carmot Therapeutics.
Cardiology December 4, 2023
Cardiac Wire Q&A: ECG Automation’s Care Impact December 4, 2023
In this Cardiac Wire Q&A, we sat down with AccurKardia CEO Juan C Jimenez and COO Mohamed Sadeq Ali to discuss ECG automation’s massive potential to improve clinical efficiency and care outcomes.
Surgeries & Interventions December 4, 2023
Medtronic and J&J’s LAA Expansions December 4, 2023
The left atrial appendage device space became far more competitive last week, following the launch of Medtronic’s Penditure LAA exclusion system and Johnson & Johnson MedTech’s acquisition of LAAX device company Laminar.
